# FULGENT GENETICS, INC. (FLGT) · Edgar & Edgarette company card

> Fulgent Genetics (FLGT) grew revenue 13.8% in FY2025 to $323 million, operating margin -28.2% against a -12.4% median for medical laboratories, equity 91.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1674930 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/FLGT) · [JSON](https://www.pops4.com/boards/company/FLGT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $323M |
| Revenue growth, 1 year | 13.8% |
| Revenue growth per year | -24.5% |
| Operating margin | -28.2% (prior year -26.1%) |
| Net margin | -19.1% |
| Operating cash flow | −$102M |
| Capital spending | $23M |
| Free cash flow | −$124M |
| Cash | $50M |
| Long-term debt | — |
| Total assets | $1.2B |
| Total equity | $1.1B |
| Equity ÷ assets | 91.6% |
| Return on equity | -5.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 14.37 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.34 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -28.2% in FY2025; revenue is hard to predict: its 80% range is ±45%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $322.7M (FY2025). Experience: revenue up 13.8% on the year, down 24.5% a year over 4 years; operating margin -28.2%, down from -26.1%. Soundness: equity 91.6% of assets, return on equity -5.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $189.7M and $504.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $148.1M to $652.6M. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin -28.2% against a -12.4% median; growth 13.8% against 13.8%.

Range logged 2026-11-01, receipt 278d49d630c72722, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-05-14 ([filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526224147/0001193125-26-224147-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526467142/0001193125-26-467142-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526449803/0001193125-26-449803-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526449799/0001193125-26-449799-index.htm)
- 10-Q · filed 2026-07-30 · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526326136/0001193125-26-326136-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/0001193125-26-326119-index.htm)
- 8-K · filed 2026-06-02 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/0001674930-26-000028-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001674930.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674930

## Cite

POPS4, Edgar & Edgarette: FULGENT GENETICS, INC. (FLGT) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/FLGT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

